Get started
Author

Anil Kumar Kanuri

Observed name: A. K. Kanuri
Observed institution: University of Malaya
ORCID: 0000-0002-1350-7148
Observed ORCID: 0000-0002-1350-7148
OpenAlex ID: A5116465364
Centella asiatica: Advances in Extraction Technologies, Phytochemistry, and Therapeutic Applications
2025 · Zaw Myo Hein, Prarthana Kalerammana Gopalakrishna, et al. · Life · 44
PDF
Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics
2022 · Vijay Kotra, Dinakar Mallem, et al. · Progress In Microbes & Molecular Biology · 9
Novel Isoxazole Functionalized Quinazolinone Derivatives and Their Anticancer Activity
2025 · S. K. Konda, A. K. Kanuri, et al. · Russian Journal of General Chemistry · 4
Nano drug delivery-benefits, limitations and future perspective
2023 · Ravi Varala, Vijay Kotra, et al. · Nano and Medical Materials · 2
PDF
A stability-indicating green RP-HPLC method for single-run quantification of ten related substances and abrocitinib, a selective JAK1 inhibitor
2026 · Nagarjuna Rao Chintanippul, B Purna Chandra Rao, et al. · Journal of Pharmaceutical Sciences · 1
Integrated GC–MS/MS and LC–MS/MS determination of potential genotoxic impurities in HER2 inhibitor tucatinib with in silico toxicological risk assessment and green analytical evaluation
2026 · Venkateswara Rao Bhoomi, Tentu Nageswara Rao, et al. · Next research. · 1
Can “Bioalchemistry” Transform Pharmaceutical Science Towards a Greener and Healthier Tomorrow?
2026 · Anil Kumar Kanuri
Quantitative characterization and in silico toxicity assessment of degradation products from the dopamine and norepinephrine reuptake inhibitor solriamfetol
2026 · Venkateswara Rao Bhoomi, Tentu Nageswara Rao, et al. · Discover Chemistry.
PDF
Works count: 8
Citation count: 61
H-index: 3
I10-index: 1
Year
Topic
Type